blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2788007

EP2788007 - USE OF SILVER(I) COMPLEXES AS ANTICANCER AGENTS [Right-click to bookmark this link]
Former [2014/42]USE OF SILVER (I) COMPLEXES AS ANTICANCER AGENTS
[2020/14]
StatusNo opposition filed within time limit
Status updated on  09.07.2021
Database last updated on 16.11.2024
FormerThe patent has been granted
Status updated on  31.07.2020
FormerGrant of patent is intended
Status updated on  31.03.2020
FormerExamination is in progress
Status updated on  02.11.2016
Most recent event   Tooltip22.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 24.08.2022  [2022/34]
Applicant(s)For all designated states
University of Johannesburg
Cnr. Kingsway and University Road
Auckland Park
Johannesburg 2006 / ZA
[N/P]
Former [2014/42]For all designated states
University of Johannesburg
Cnr. Kingsway and University Road Auckland Park
Johannesburg 2006 / ZA
Inventor(s)01 / MEIJBOOM, Reinout
15 Ararat Street
Westdene
2092 Johannesburg / ZA
02 / CRONJÉ, Marianne Jacqueline
20 Felspar Road
Wilro Park
1725 Roodepoort / ZA
 [2014/42]
Representative(s)Michalski Hüttermann & Partner Patentanwälte mbB
Kaistraße 16A
40221 Düsseldorf / DE
[N/P]
Former [2014/42]Michalski Hüttermann & Partner Patentanwälte mbB
Speditionstraße 21
40221 Düsseldorf / DE
Application number, filing date12813988.806.12.2012
[2020/36]
WO2012IB57029
Priority number, dateZA2011000894406.12.2011         Original published format: ZA 201108944
[2014/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013084185
Date:13.06.2013
Language:EN
[2013/24]
Type: A1 Application with search report 
No.:EP2788007
Date:15.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 13.06.2013 takes the place of the publication of the European patent application.
[2014/42]
Type: B1 Patent specification 
No.:EP2788007
Date:02.09.2020
Language:EN
[2020/36]
Search report(s)International search report - published on:EP13.06.2013
ClassificationIPC:A61K33/38, A61K31/66, A61K35/00
[2020/14]
CPC:
A61K33/38 (EP,US); A61K31/28 (US); A61K31/095 (US);
A61K31/66 (EP,US); A61K49/0004 (US); C07F9/5442 (US)
Former IPC [2014/42]A61K33/38, A61K35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/42]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON SILBER-(I-)KOMPLEXEN ALS ANTIKREBSMITTEL[2014/42]
English:USE OF SILVER(I) COMPLEXES AS ANTICANCER AGENTS[2020/14]
French:UTILISATION DE COMPLEXES D'ARGENT (I) EN TANT QU'AGENTS ANTICANCÉREUX[2014/42]
Former [2014/42]USE OF SILVER (I) COMPLEXES AS ANTICANCER AGENTS
Entry into regional phase17.06.2014National basic fee paid 
17.06.2014Designation fee(s) paid 
17.06.2014Examination fee paid 
Examination procedure05.10.2013Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.06.2014Examination requested  [2014/42]
27.10.2014Amendment by applicant (claims and/or description)
24.10.2016Despatch of a communication from the examining division (Time limit: M04)
02.03.2017Reply to a communication from the examining division
28.07.2017Despatch of a communication from the examining division (Time limit: M06)
01.02.2018Reply to a communication from the examining division
04.04.2019Despatch of a communication from the examining division (Time limit: M02)
13.06.2019Reply to a communication from the examining division
18.09.2019Despatch of a communication from the examining division (Time limit: M02)
08.11.2019Reply to a communication from the examining division
01.04.2020Communication of intention to grant the patent
23.07.2020Fee for grant paid
23.07.2020Fee for publishing/printing paid
23.07.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.10.2016
Opposition(s)03.06.2021No opposition filed within time limit [2021/32]
Fees paidRenewal fee
22.12.2014Renewal fee patent year 03
22.12.2015Renewal fee patent year 04
23.12.2016Renewal fee patent year 05
21.12.2017Renewal fee patent year 06
19.12.2018Renewal fee patent year 07
23.12.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.12.2012
AL02.09.2020
AT02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
MK02.09.2020
MT02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
TR02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
BE31.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
[2022/34]
Former [2022/32]HU06.12.2012
AL02.09.2020
AT02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
MK02.09.2020
MT02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
TR02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
Former [2022/27]HU06.12.2012
AL02.09.2020
AT02.09.2020
CY02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
MT02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
TR02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
Former [2022/26]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
TR02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
Former [2022/23]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
Former [2022/10]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
PT04.01.2021
Former [2021/52]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
CH31.12.2020
FR31.12.2020
LI31.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/49]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
GB06.12.2020
IE06.12.2020
LU06.12.2020
FR31.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/48]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
IT02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IE06.12.2020
LU06.12.2020
FR31.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/47]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IE06.12.2020
LU06.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/46]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IE06.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/40]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
MC02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/37]AL02.09.2020
AT02.09.2020
CZ02.09.2020
DK02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/36]AL02.09.2020
AT02.09.2020
CZ02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SI02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/28]AL02.09.2020
AT02.09.2020
CZ02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SK02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/25]AL02.09.2020
AT02.09.2020
CZ02.09.2020
EE02.09.2020
ES02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
IS02.01.2021
PT04.01.2021
Former [2021/24]AT02.09.2020
CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/23]CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
SM02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/22]CZ02.09.2020
EE02.09.2020
FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RO02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/21]FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
PT04.01.2021
Former [2021/18]FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
NL02.09.2020
PL02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
Former [2021/10]FI02.09.2020
HR02.09.2020
LT02.09.2020
LV02.09.2020
PL02.09.2020
RS02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
Former [2021/09]FI02.09.2020
LT02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
GR03.12.2020
Former [2021/08]FI02.09.2020
LT02.09.2020
SE02.09.2020
BG02.12.2020
NO02.12.2020
Former [2021/07]FI02.09.2020
LT02.09.2020
NO02.12.2020
Cited inInternational search[X]US4857549  (HILL DAVID T [US], et al) [X] 1-13 * example 27 * * claims 1-14 *;
 [X]EP0372313  (HOECHST AG [DE]) [X] 4,11-13 * example 30 *;
 [X]US2003207568  (BYUN YOUNG HUN [KR], et al) [X] 4,11-13 * examples 2,3 *;
 [X]WO2010084315  (UNIV BATH [GB], et al) [X] 4,11-13 * example IA *;
 [X]WO2011089780  (CENTRAL GLASS CO LTD [JP], et al) [X] 4,11-13 * examples 1-9 * * claims 1-5 *;
 [XI]  - SANTINI C ET AL, "In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands", JOURNAL OF INORGANIC BIOCHEMISTRY, ELSEVIER INC, US, vol. 105, no. 2, ISSN 0162-0134, (20110201), pages 232 - 240, (20101229), XP027578563 [X] 4,11-13 * Synthesis of compound (5) Results part of the document * [I] 1-10
 [XI]  - POYRAZ M ET AL, "Synthesis, structural characterization and biological studies of novel mixed ligand Ag(I) complexes with triphenylphosphine and aspirin or salicylic acid", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 375, no. 1, doi:10.1016/J.ICA.2011.04.032, ISSN 0020-1693, (20110420), pages 114 - 121, (20110505), XP028259894 [X] 4,11-13 * Synthesis of the compounds. Results part of the document. * [I] 1-3,5-10

DOI:   http://dx.doi.org/10.1016/j.ica.2011.04.032
 [XI]  - ZARTILAS S ET AL, "Tetrameric 1:1 and monomeric 1:3 complexes of silver(I) halides with tri(p-tolyl)-phosphine: A structural and biological study", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 362, no. 3, doi:10.1016/J.ICA.2007.07.034, ISSN 0020-1693, (20090220), pages 1003 - 1010, (20090131), XP025928142 [X] 4,11-13 * items 2.1, 2.4 * [I] 1-3,5-10

DOI:   http://dx.doi.org/10.1016/j.ica.2007.07.034
 [XI]  - KYROS L ET AL, "Structural properties, cytotoxicity, and anti-inflammatory activity of silver(I) complexes with tris(p-tolyl)phosphine and 5-chloro-2-mercaptobenzothiazole.", BIOINORGANIC CHEMISTRY AND APPLICATIONS, (2010), ISSN 1687-479X, pages 1 - 12, XP002692154 [X] 4,11-13 * items 4.2, 4.5 * [I] 1-12

DOI:   http://dx.doi.org/10.1155/2010/386860
 [X]  - POULTER NEIL ET AL, "An organo-silver compound that shows antimicrobial activity against Pseudomonas aeruginosa as a monomer and plasma deposited film.", CHEMICAL COMMUNICATIONS, (CAMBRIDGE, ENGLAND), (20091221), no. 47, ISSN 1364-548X, pages 7312 - 7314, XP009167090 [X] 13 * page 7312, column r, paragraph 5 *

DOI:   http://dx.doi.org/10.1039/b915467a
 [XI]  - LIU ET AL, "In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake", JOURNAL OF INORGANIC BIOCHEMISTRY, ELSEVIER INC, US, (20080116), vol. 102, no. 2, doi:10.1016/J.JINORGBIO.2007.09.003, ISSN 0162-0134, pages 303 - 310, XP022423139 [X] 4,11,12 * the whole document * [I] 1-3,5-10

DOI:   http://dx.doi.org/10.1016/j.jinorgbio.2007.09.003
Examination   - OMONDI, "Concomitant polymorphic behavior of di-thiocyanato 2bis[bis(tri-p-fiuorophenyiphosphine-P)silver(l)", ACTA CRYST, (20101020), pages 69 - 75
by applicant   - BAGULEY, B.C.; BEMERS-PRICE, S.J.; BOWEN, R.J.; FARR, A.; GALETTIS, P.; LIU; J.J.; MAHARAJ, L.; MCGECHAN, A.C.; MCKEAGE, M.J.; SAM, "In vitro antitumor and hepatotoxicity profiles of Au(i) and Ag(l) bidentate pyridyl phosphine complexes and relationships to cellular uptake", JOURNAL OF INORGANIC BIOCHEMISTRY, (2008), vol. 102, pages 303 - 310
    - BARNARD, P.J.; BERNERS-PRICE, S.J., "Targeting the mitochondrial cell death pathway with gold compounds", CO-ORDINATION CHEMISTRY REVIEWS, (2007), vol. 251, no. 13-14, pages 1889 - 1902
    - BAYIR, H.; KAGAN. V.E., "Bench-to-bedside review: Mitochondrial injury, oxidative stress and apoptosis - there is nothing more practical than a good theory", CRITICAL CARE, (2008), vol. 12, page 206
    - BELLO, B.O.; FADAHUN ET AL., "Trends in lung cancer mortality in South Africa: 1995-2006", BMC PUBLIC HEALTH, (2011), vol. 11, no. 1, page 209
    - "Structure and bonding, Phosphine and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity", BERNERS-PRICE, S.J.; SADLER P.J., Bioinorganic Chemistry, SPRINGER BERLIN, (1988), vol. 70, pages 27 - 102
    - BERNERS-PRICE, S.J.; BOWEN, R.J.; GALETTIS, P.; HEALY, P.C.; MCKEAGE, M.C., "Structural and solution chemistry of gold(l) and silver(l) complexes of bidentate pyridyl phosphines: selective antitumour agents", COORDINATION CHEMISTRY REVIEWS, (1999), vol. 185-186, pages 823 - 836
    - BERNERS-PRICE, S.J.; BOWEN, R.J.; HARVEY, P.J.; HEALY, P.C.; KOUTSANTONIS, G.A., J. CHEM. SOC., DALTON TRANSACTIONS, (1998), pages 1743 - 1750
    - BIRD-LIEBERMAN, E.L.; FITZGERALD R.C., "Early diagnosis of oesophageal cancer", BRITISH JOURNAL OF CANCER, (2009), vol. 101, pages 1 - 6
    - BOLD, R.J.; TERMUHLEN, P.M.; MCCONKEY, D.J, "Apoptosis, cancer and cancer therapy", SURGICAL ONCOLOGY, (1997), vol. 6, pages 133 - 142
    - BRANDYS, M.C.; PUDDEPHATT R.J., "Polymeric complexes of silver(l) with diphosphine ligands: self- assembly of a puckered sheet network structure", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2002), vol. 124, no. 15, pages 3946 - 3950
    - BRESSAC-DE-PAILLERETS, B.; AVRIL, M.F.; CHOMPRET, A.; DEMENAIS, F, "Genetic and environmental factors in cutaneous malignant melanoma", BIOCHIMIE, (2002), pages 67 - 74
    - CHABNER, B.A.; ROBERTS T.G., "Chemotherapy and the war on cancer", NATURE REVIEWS, (2005), vol. 5, pages 65 - 72
    - CHOWDHURY, I.; THARAKAN, B.; BHAT, G.K., CASPASES - AN UPDATE. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, (2008), vol. 151, pages 10 - 27
    - COTTER, T.G., "Apoptosis and cancer: the genesis of a research field", NATURE REVIEWS CANCER, (2009), vol. 9, no. 7, pages 501 - 507
    - DANIAL, N.N.; KORSMEYER, S.J., "Cell death: critical control points", CELL, (2004), vol. 116, pages 205 - 219
    - ELMORE, S., APOPTOSIS: A REVIEW OF PROGRAMMED CELL DEATH: TOXICOLOGICAL PATHOLOGY, (2007), vol. 35, pages 495 - 516
    - ENZINGER, P.C.; MAYER R.J., "Esophageal Cancer", NATIONAL ENGLISH JOURNAL OF MEDICINE, (2003), vol. 349, pages 2241 - 52
    - "Globocan", FERLAY, J.; SHIN H.R.; BRAY F.; FORMAN D.; MATHERS C.; PARKIN, D.M., Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, (2008), vol. 1.2
    - FERLAY, J.; SHIN ET AL., "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", INTERNATIONAL JOURNAL OF CANCER, (2010), vol. 127, no. 12, pages 2893 - 2917
    - FESTJENS, N.; VANDEN BERGHE, T.; VANDENABEELE, P., "Necrosis, a well-orchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response", BIOCHIMICA ET BIOPHYSICA ACTA, (2006), vol. 1757, pages 1371 - 1387
    - FISCHER, S.J.; BENSON, L.M.; FAUQ, A.; NAYLOR, S.; WINDERBANK, A.J., "Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity", NEUROTOXICOLOGY, (2008), vol. 29, pages 444 - 452
    - FISCHER, U.; SCHULZE-OSTHOFF K, "Apoptosis-based and drug targets", CELL DEATH AND DIFFERENTIATION, (2005), vol. 12, pages 942 - 961
    - GARBE, C.; PERIS, K.; HAUSCHILD A.; SALAG, P.; MIDDLETON, M.; SPATZ, A.; GROB, J.J.; MALVEHY, J.; NEWTON-BISHOP, J.; STRATIGOS, A., "Diagnosis and treatment of melanoma: Europeanconsensus-based interdisciplinary guideline", EUROPEAN JOURNAL OF CANCER, (2010), vol. 46, pages 270 - 283
    - GIBLIN, A.V.; THOMAS, J.J., "Incidence, morality and survival in cutaneous melanoma", JOURNAL OF PLASTIC, RECONSTRUCTIVE AND AESTHETIC SURGERY, (2007), vol. 60, no. 1, pages 32 - 40
    - GOLSTEIN, P.; KROEMER, G., "Cell death by necrosis: Towards a molecular definition", TRENDS IN BIOCHEMICAL SCIENCES, (2007), vol. 32, pages 37 - 43
    - HANAHAN, D.; WEINBURG R.A., "The hallmarks of cancer", CELL, (2000), vol. 100, pages 57 - 70
    - HOLDENRIEDER, S.; STIEBER, P., "Apoptotic markers in cancer", CLINICAL BIOCHEMISTRY, (2004), vol. 37, pages 605 - 617
    - JIMENEZ DEL RIO, M.; VELEZ-PARDO, C., "Transition metal induced apoptosis in lymphocytes via hydroxyl radical generation, mitochondria dysfunction and caspase-3 activation: an in vitro model for neurodegeneration", MEDICAL RESEARCH, (2004), vol. 35, no. 3, pages 185 - 193
    - KERR, J.F.R.; WYLLIE A.H.; CURRIE A.R., "Apoptosis: a basic biological phenomenon with wide-ranging implication in tissue kinetics", BRITISH JOURNAL OF CANCER, (1972), vol. 26, pages 239 - 257
    - KERR, J.F.R., "Apoptosis: Its significance in cancer and cancer therapy", CANCER, (1994), vol. 73, no. 8, pages 2013 - 2022
    - KHUMALO, N.M.; MEIJBOOM, R.; MULLER, A.; OMONDI, B., ACTA CRYST., (2010), vol. E66, page M451
    - KING, K.L.; CIDLOWSKI, J.A., "Cell cycle regulation and apoptosis", ANNUAL REVIEW OF PHYSIOLOGY, (1998), vol. 60, pages 601 - 617
    - KROEMER, G.; GALUZZI, L.; BRENNER, C., "Mitochondrial membrane permeabilization in cell death", PHYSIOLOGICAL REVIEWS, (2007), vol. 87, pages 99 - 163
    - KROEMER, G.; GALLUZZI L.; VANDENABEELE P.; ABRAMS J.; ALNEMRI E.S.; BAEHRECKE E.H.; BLAGOSKLONNY M.V.; EL-DEIRY W.S.; GOLSTEIN P.;, "Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009", CELL DEATH AND DIFFERENTIATION, (2009), vol. 16, pages 3 - 11
    - LIN, A.W.; LOWE, S.W., "Apoptosis in cancer", CARCINOGENESIS, (2000), vol. 21, pages 485 - 495
    - LIU, J.J.; GALETTIS, P.; FARR, A.; MAHARAJ, L.; SAMARASINHA, H.; MCGECHAN, A.C.; BAGULEY, B.C.; BOWEN, R.J.; BERNERS-PRICE, S.J.;, "In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(l) bidentate pyridyl phosphine complexes and relationships to cellular uptake", JOURNAL OF INORGANIC BIOCHEMISTRY, (2008), vol. 102, no. 2, pages 303 - 310
    - LOWE, S.W.; CEPERO, E.; EVAN, G., "Intrinsic tumour suppression", NATURE, (2004), vol. 432, pages 307 - 315
    - MANN, F.G.; WELLS, A.F.; PURDUE, D., J. CHEM. SOC., (1937), page 1828
    - MCCABE, M.L.; DLAMINI, Z., "The molecular mechanisms of oesophageal cancer", INTERNATIONAL PHARMACOLOGY, (2005), vol. 5, pages 1113 - 1130
    - MEIJBOOM, R.; BOWEN, R.J.; BERNERS-PRICE, S.J., "Coordination complexes of silver(l) with tertiary phosphine and related ligands", COORD. CHEM. REV., (2009), vol. 253, pages 325 - 342
    - MIZUSHIMA, N., "Methods for monitoring autophagy", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, (2004), vol. 36, pages 2491 - 2502
    - NGUYEN, J.T.; WELLS J.A., "Direct activation of the apoptosis machinery as a mechanism to target cancer cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2003), vol. 100, pages 7533 - 7538
    - OMONDI, B.; MEIJBOOM, R., ACTA CRYST., (2010), vol. B66, page 69
    - PIAO, M.J.; KIM, K.; CHOI, J.; CHOI, J.; WON HYUN, J., "Silver nanoparticles down-regulate Nrf2- mediated 8-oxoguanine DNA glycosylase 1 through inactivation of extracellular regulated kinase and protein kinase B in human Chang liver cells", TOXICOLOGY LETTERS, (2010), vol. 207, pages 143 - 148
    - PIAO, M.J.; AH KANG, K.; LEE, I.K.; KIM, H.S.; KIM, S.; CHOI, J-Y ET AL., "Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis", TOXICOLOGY LETTERS, (2011), vol. 201, pages 92 - 100
    - PITOT, H.C., Fundamental of Oncology, MARCEL DEKKER INC, (2002), page 27,901
    - RACKHAM, D.; NICHOLS, S.J.; LEEDMAN, P.J.; BERNERS-PRICE, S.J.; FILIPOVSKA, A., "Gold(I) phosphine complex selectivity induces apoptosis in breast cancer cells: Implication for Anti-cancer therapeutics targeted to mitochondria", BIOCHEMICAL PHARMACOLOGY, (2007), vol. 74, pages 992 - 1002
    - REED. J.C., "Dysregulation of apoptosis in cancer", JOURNAL OF CLINICAL ONCOLOGY, (1999), vol. 17, pages 2941 - 2953
    - REEDIJK, J., "New dues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2003), vol. 7, pages 3611 - 3616
    - SADLER, P.J.; GUO, Z., "Metal complexes in medicine: Design and mechanism of action", PURE AND APPLIED CHEMISTRY, (1998), vol. 70, no. 4, pages 863 - 875
    - SAWAMURA, M.; HAMASHIMA, H.; ITO, Y., "The asymmetric aldol reaction of tosylmethyl isocyanide and aldehydes catalyzed by chiral silver(l) complexes", JOURNAL OF ORGANIC CHEMISTRY, (1990), vol. 55, no. 24, pages 5935 - 5936
    - SCHERER, D.; KUMAR R., "Genetics of pigmentation in skin cancer - A review", MUTATION RESEARCH, (2010), vol. 705, pages 141 - 153
    - SEGAPELO, T.V.; GOZEI, I.A.; SPENCER, L.C.; VAN ZYL, W.E., "Pyrazolylmethyl) Pyridine platinum (II) and gold (III) complexes: synthesis structures and evaluation as anticancer agents", INORGANICA CHEMICA ACTA, (2009), vol. 362, pages 3316 - 3324
    - SIMSTEIN, R.; BUROW, M.; PARKER, A.; WELDON, C.; BECKMAN, B., "Apoptosis, chemoresistance and breast cancer: Insights from the MCF-7 cell model system", EXPERIMENTAL BIOLOGY AND MEDICINE, (2003), vol. 228, pages 995 - 1003
    - TEODORO, J.S.; SIMOES A.M.; DUARTE, F.V.; ROLO, A.P.; MURDOCH, R.C.; HYUSSAIN, S.M.; PALMEIRA, C.M., "Assessment of the toxicity of silver nanoparticles in vitro: A mitochondrial perspective", TOXICOLOGY IN VITRO, (2011), pages 25664 - 670
    - VENTER, G.J.S.; MEIJBOOM, R.; ROODT, A., ACTA CRYST., (2007), vol. E63, page M3076
    - VOGELSTEIN, B.; KINZIER, K.W., "Cancer genes and the pathways they control", NATURE MEDICINE, (2004), vol. 10, no. 8, pages 789 - 799
    - VOROBIOF, D.A.; SITAS, F.; VOROBIOF, G., "Breast cancer incidence in South Africa", JOURNAL OF CLINICAL ONCOLOGY, (2001), vol. 19, pages 125S - 127S
    - WANG, Z.-B.; LIU, Y.-Q.; CUI, Y.-F., "Pathways to caspase activation", CELL BIOLOGY INTERNATIONAL, (2005), vol. 29, pages 489 - 496
    - HADJIKALAS ET AL., "Tetrameric 1:1 and monomeric 1:3 complexes of silver (I) halides with tri 9p-tolyl) phosphine: a structural and biological study", INORGANICA CHEMICA ACTA, (2009), vol. 362, pages 1003 - 1010
    - ZHANG, A.; WU, Y.; LAI, H.W.L.; YEW, D.T., "Apoptosis - A Brief Review", NEUROEMBRYOLOGY, (2004), vol. 5, no. 3, pages 47 - 59
    - ZHIVOTOVSKY, B; KROEMER G., "Apoptosis and genomic instability", NATURE REVIEWS MOLECULAR CELL DIOLOGY, (2004), vol. 5, pages 752 - 762
    - ZIMMERMANN, K.C.; BONZON C.; GREEN D.R., "The machinery of programmed cell death", PHARMACOLOGY AND THERAPEUTICS, (2001), vol. 92, pages 57 - 70
    - ZONG, W.-X.; THOMPSON, C.B., "Necrotic death as a cell fate", GENES AND DEVELOPMENT, (2006), vol. 20, pages 1 - 15
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.